ImmunoVaccine Technologies Licenses Immunotope’s Breast, Ovarian and Prostate Cancer Antigens

16-Jul-2009 - Canada

ImmunoVaccine Technologies Inc. (IVT) has entered into an agreement to exclusively license seven cancer antigens from Immunotope Inc., an antigen discovery company. These proprietary antigens specifically target breast, ovarian and prostate cancers. IVT will combine the proprietary antigens with its DepoVax™ delivery platform to develop DPX-0907, a therapeutic cancer vaccine. Within the next six months the company will fast-track DPX-0907 into Phase 1 clinical trials.

Under the license agreement, IVT has agreed to an up-front payment, as well as future milestone payments and royalties to Immunotope for use of the antigens. This licensing agreement replaces the acquisition of Immunotope agreement.

DPX-0907 is a novel vaccine because of its potential to create a depot at the injection site and cause a strong, rapid, long-lasting immune response that specifically targets cancer cells.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

Last viewed contents